Document:

Director Agreement

 

This Agreement is entered into by and between Lightlake Therapeutics
Inc. (the “Company”) and Geoffrey Wolf (“Wolf”) (collectively, the “Parties”) dated November
26, 2012 (the “Letter”), on December 31st, 2012 (the “Agreement”).

 

WHEREAS Wolf is a Director of the Company;

 

WHEREAS the Company has requested that Wolf provide additional
services beneficial to the Company beyond the scope of what Wolf has previously provided to the Company (the “Services”);

 

WHEREAS Wolf has received compensation deemed by the Company
to be inadequate to retain Wolf as a Director;

 

WHEREAS the Company seeks to retain Wolf as a Director; and

 

WHEREAS the Company seeks to provide Wolf with additional incentive
to remain a Director and perform the Services;

 

NOW THEREFORE, in consideration of the mutual covenants herein
contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby mutually agree to amend the Letter as follows:

 

		1)	Wolf shall provide the Services until one (1) year from the date hereof.

 

		2)	Any compensation granted herein shall be in addition to any other option compensation previously granted by the Company to
Wolf.

 

		3)	Wolf shall be granted stock options for three million five hundred thousand (3,500,000) shares of stock of the Company, exercisable
at US$0.15 (“Exercise Price”) with the life of such options being five (5) years (collectively, the “Options”).
Such Options shall be exercisable in the form of Notice of Stock Option Grant attached as Exhibit A hereto, which Options may be
exercised, where applicable, pursuant to the form of Notice of Exercise of Stock Option (the “Exercise Notice”) attached
as Exhibit B hereto. Notwithstanding any provisions of the Options to the contrary, if the fair market value of one share of Common
Stock (as defined in the Stock Option Plan of the Company effective December 15, 2010 (the “Stock Option Plan”)) is
greater than the exercise price (at the date of calculation as set forth below), in lieu of exercising the Options for cash, the
Holder (as defined in the Stock Option Plan) may elect to receive shares equal to the value (as determined below) of the Options
(or the portion thereof being exercised) by surrender of the Options at the principal office of the Company together with the properly
signed Exercise Notice in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the
following formula:

 

    	 

    	 

    

 

 

	X=	Y(A-B)
	 	      A
	 	 
	Where X =	the number of shares of Common Stock to be issued to the Holder
	 	 
	Y =	the number of shares of Common Stock purchasable under the Options or, if only a portion of the Options are being exercised, the portion of the Options being exercised (at the date of such calculation)
	 	 
	A =	the fair market value of one share of the Company’s Common Stock (at the date of such calculation)
	 	 
	B =	the Exercise Price per share (as adjusted to the date of such calculation)

 

Notwithstanding the foregoing, such Options may only
be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s Common Stock
has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) their
expiration date. Proportionate adjustments shall automatically be made to both the Exercise Price and number of such Options, and
the price per share restriction set forth in this paragraph, in the event of a stock split, stock dividend, reclassification, recapitalization,
or any other increase or decrease in the number of issued shares of the Company’s Common Stock effected without receipt of
consideration by the Company, or upon any other event reasonably determined by a majority of the Board of Directors of the Company
to justify such adjustments.

 

All such Options delivered to Wolf as per this Agreement
may be delivered to Wolf electronically with a scanned signature, in which case they shall have the same effect and force as if
they had been delivered in original signed form. For all Options granted to Wolf electronic delivery of a signed Exercise Notice
along with electronic delivery of such Options shall have the same exercise effect as surrendering such Options at the principal
office of the Company together with the properly signed Exercise Notice.

 

Within one (1) month following the date hereof, the
Company shall deliver to Wolf all Options granted herein. All shares of the Company’s Common Stock underlying the Options
set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date hereof, the Company
shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely transferrable
Common Stock shall be delivered to Wolf upon the exercise of the Options.

 

    	 

    	 

    

 

		4)	Wolf shall be granted warrants for thirty four million five hundred thousand (34,500,000) shares of stock of the Company, exercisable
at US$0.15 with the life of such warrants being five (5) years from the date hereof (the “Warrants”). Such Warrants
shall be exercisable in the form of Notice of Warrant Grant attached as Exhibit C hereto, which Warrants may be exercised, where
applicable, pursuant to the form of Notice of Exercise of Warrant (the “Warrant Exercise Notice”) attached as Exhibit
D hereto. The Warrants shall be exercisable in whole or in part, are only exercisable for cash, and are freely transferable to
other parties, except as prohibited by applicable laws and regulations. Subject to the restrictions and requirements of applicable
law, the Warrants are exchangeable at any time for an equal aggregate number of warrants of different denominations, as reasonably
requested by the holder of the Warrants surrendering the same, or in such denominations as may be requested by the holder of the
Warrants (but not exceeding the number of Warrants granted).

 

Notwithstanding the foregoing, such Warrants may only
be exercised between the following dates: (i) the earliest date on which the price per share of the Company’s Common Stock
has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) their
expiration date. Proportionate adjustments shall automatically be made to both the Exercise Price and number of such Warrants,
and the price per share restriction set forth in this paragraph, in the event of a stock split, stock dividend, reclassification,
recapitalization, or any other increase or decrease in the number of issued shares of the Company’s Common Stock effected
without receipt of consideration by the Company, or upon any other event reasonably determined by a majority of the Board of Directors
of the Company to justify such adjustments.

 

Within one (1) month following the date hereof, the
Company shall deliver to Wolf such Warrants in original signed form. For all Warrants granted to Wolf electronic delivery of a
signed Warrant Exercise Notice along with electronic delivery of such Warrants shall have the same exercise effect as surrendering
such Warrants at the principal office of the Company together with the properly signed Warrant Exercise Notice.

 

All shares of the Company’s Common Stock underlying
the Warrants set forth above shall be delivered in registered and freely transferrable form. Within one (1) year from the date
hereof, the Company shall register all such stock under the Securities Act of 1933, as amended, to ensure that registered and freely
transferrable Common Stock shall be delivered to Wolf upon the exercise of the Warrants.

 

    	 

    	 

    

 

		5)	In the event of termination of this Agreement, the Company shall not be obligated to provide any further compensation to Wolf
except such options that have vested, such warrants that have been granted, and any other compensation to which Wolf is entitled
through the date of such termination.

 

		6)	This Agreement shall be governed by and construed in accordance with the laws of the United States, and specifically the laws
of the state of Nevada. Should a dispute arise, both parties shall subject themselves to exclusive jurisdiction of the courts of
the state of Nevada.

 

		7)	This Agreement constitutes the entire understanding between the Parties relating to its subject matter, superseding all negotiations,
prior discussions, preliminary agreements and agreements relating to the subject matter hereof made prior to the date hereof. No
waiver by a Party of any breach by another Party of any term, provision or condition of this Agreement, to be performed by such
other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or at any prior or subsequent
time. This Agreement may not be modified or amended except in writing signed by the Parties. Each of the Parties hereto agrees
that this Agreement has been jointly prepared, and that no claim may be asserted by any Party that any ambiguity in this Agreement
may be construed against any one Party.

 

		8)	This Agreement may be executed in counterparts, each of which shall constitute an original but together shall constitute one
and the same Agreement. The Parties further agree that such counterparts may be provided via scan, email, and/or facsimile to one
another, each of which shall be binding upon the signatory who sends the scan, email and/or facsimile that was signed by such sending
signatory. The Parties further agree to exchange the original signature pages hereof as soon as practicable after sending such
scan, email and/or facsimile, but in any dispute or controversy, the Parties hereto agree that it shall not be necessary for any
such Party to provide the original signature pages of the other as a condition of enforcing this Agreement, it being understood
that such scan, email and/or facsimile signature pages shall be sufficient to establish the consent of the Party who sent the scan,
email and/or facsimile that was signed by such sending signatory to be bound by the terms of this Agreement.

 

IN WITNESS WHEREOF the parties have executed
this Agreement this 31st day of December 2012.

 

LIGHTLAKE THERAPEUTICS INC.

 

	By:	/s/ Roger Crystal	 
	Name:	Roger Crystal	 
	Title:	CEO	 
	 	 	 
	By:	/s/ Geoffrey Wolf	 
	Name:	Geoffrey Wolf	 
	Title:	Mr.	 

 

    	 

    	 

    

 

EXHIBIT A

 

FORM OF NOTICE OF STOCK OPTION GRANT

 

Dear Mr. ________________ (“Optionee”),

 

Reference is hereby made to (i) the Stock Option Plan of Lightlake
Therapeutics Inc. (the “Company”) effective December 15, 2010 (the “Stock Option Plan”),
and (ii) the Director Agreement dated _______________ __, ____, between the Company and Geoffrey Wolf (as amended, restated, or
otherwise modified from time to time, the “Letter”). Capitalized terms utilized herein shall have the meanings
ascribed to them in the Stock Option Plan unless otherwise defined herein.

 

You have been granted
options to purchase Common Stock of the Company (with each share of Common Stock of the Company, a “Share”)
as follows:

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	US$0.15
	 	 
	Total Number of Shares Granted:	 
	 	 
	Total Exercise Price:	Cashless exercise as per the Letter
	 	 
	Type of Options:	Non-Qualified Stock Options
	 	 
	Expiration Date:	[The date that is five (5) years from the Date of Grant]
	 	 
	Termination Period:	These Options may be exercised for a period of five (5) years from the Date of Grant.  Optionee is responsible for keeping track of these exercise periods following termination for any reason of his service relationship with the Company, it being understood that Optionee is entitled to all rights, including compensation and vesting rights, with respect to this Option, as set forth in the Letter.  The Company will not provide further notice of such periods.

 

    	 

    	 

    

 

	Transferability:	These Options may not be transferred, except as permitted by applicable laws and regulations.
	 	 
	Restrictions on Exercise:	These Options may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.  Notwithstanding anything to the contrary contained in any agreement with the Company, it is an absolute condition of the Optionee’s right to exercise any Option that the Optionee be in full compliance with any other agreements between the Optionee and the Company, including without limitation any confidentiality agreements.
	 	 
	Vesting:	100% on [the date of the Director Agreement referenced herein]

 

Following receipt by
the Company of evidence and/or an indemnity from the Optionee to the Company in a form reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of these Options or any certificates for representing the Shares underlying these Options
and, in the event of mutilation, following the surrender and cancellation of such Options or stock certificate, the Company will
make and deliver replacement Options or stock certificate of like tenor and dated as of such cancellation, in lieu of these Options
or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement Options
or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Options or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Options and any Shares underlying these Options. Subject
to the restrictions and requirements of applicable law, these Options are exchangeable at any time for an equal aggregate number
of options of different denominations, as reasonably requested by the Optionee surrendering the same, or in such denominations
as may be requested by the Optionee (but not exceeding the number of Shares underlying the Options in these Options in the aggregate). 
No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments shall automatically
be made to both the Exercise Price and number of these Options, and the Restrictions on Exercise, in the event of a stock split,
stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued Shares of the Company
effected without receipt of consideration by the Company, or upon any other event reasonably determined by a majority of the Board
of Directors of the Company to justify such adjustments.

 

    	 

    	 

    

 

Shares issued to you
upon exercise of these Options shall be registered under the Securities Act of 1933, as amended, and shall be freely transferrable.
To the extent that the terms of the Stock Option Plan differ from the terms of this Notice of Stock Option Grant (the “Notice”),
the terms of this Notice supersede the terms of the Stock Option Plan.

 

By your signature and
the signature of the Company’s representative below, you and the Company agree to the terms of these Options.

 

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Optionee	 	Roger Crystal, Chief Executive Officer

 

EXHIBIT B

 

Form of Notice of Exercise of Stock
Option

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the stock option(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such option(s), I wish to purchase _______________ shares of the common stock covered by such option(s) at the exercise price(s)
of US$ ______ per share via cashless exercise. These shares should be registered under the Securities Act of 1933, as amended,
and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

    	 

    	 

    

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Name:	 	 

 

EXHIBIT C

 

FORM OF NOTICE OF WARRANT GRANT

 

Dear ________________ (“Warrant Holder”),

 

As per the Director Agreement
dated _______________ __, ____, between Lightlake Therapeutics Inc. (the “Company”) and Geoffrey Wolf, the Warrant
Holder has been granted warrants (“Warrants”) to purchase Common Stock of the Company (with each share of Common Stock
of the Company, a “Share”) as follows:

 

 

	Board Approval Date:	 
	 	 
	Date of Grant:	 
	 	 
	Exercise Price per Share:	US$0.15
	 	 
	Total Number of Warrants Granted:	 
	 	 
	Total Exercise Price:	US$0.15 per Warrant
	 	 
	Expiration Date:	[The date that is five (5) years from the Date of Grant]
	 	 
	Termination Period:	These Warrants may be exercised for a period of five (5) years from the Date of Grant.

 

    	 

    	 

    

 

	Transferability:	These Warrants may be transferred, except as prohibited by applicable laws and regulations.
	 	 
	Vesting:	100% on [the date of the Director Agreement referenced herein.]
	 	 
	Restriction on Exercise:	These Warrants may only be exercised between the following dates: (i) the earliest date on which the price per Share has traded at or above US$0.30 for at least three (3) trading days out of any ten (10) consecutive trading days; and (ii) the Expiration Date.

 

Following receipt by
the Company of evidence and/or an indemnity from the Warrant Holder to the Company in a form reasonably satisfactory to the Company
of the loss, theft, destruction or mutilation of these Warrants or any certificates for representing the Shares underlying these
Warrants and, in the event of mutilation, following the surrender and cancellation of such Warrants or stock certificate, the Company
will make and deliver replacement Warrants or stock certificate of like tenor and dated as of such cancellation, in lieu of these
Warrants or stock certificates, without any charge therefor, it being understood that the making and/or delivery of such replacement
Warrants or stock certificates by the Company will not be unreasonably withheld.  Any such replacement Warrants or stock certificates
shall be subject to the same terms, conditions, and restrictions as these Warrants and any Shares underlying these Warrants. Subject
to the restrictions and requirements of applicable law, these Warrants are exchangeable at any time for an equal aggregate number
of warrants of different denominations, as reasonably requested by the Warrant Holder surrendering the same, or in such denominations
as may be requested by the Warrant Holder (but not exceeding the number of Shares underlying the Warrants in these Warrants in
the aggregate).  No service charge will be made for such registration or transfer, exchange or reissuance. Proportionate adjustments
shall automatically be made to both the Exercise Price and number of these Warrants, and the Restriction on Exercise, in the event
of a stock split, stock dividend, reclassification, recapitalization, or any other increase or decrease in the number of issued
Shares of the Company effected without receipt of consideration by the Company, or upon any other event reasonably determined by
a majority of the Board of Directors of the Company to justify such adjustments.

 

Shares issued to the
Warrant Holder upon exercise of these Warrants shall be registered under the Securities Act of 1933, as amended, and shall be freely
transferrable.

 

By signature of the
Warrant Holder and the signature of the Company’s representative below, the Warrant Holder and the Company agree to the
terms of these Warrants. 

 

    	 

    	 

    

  

	 	 	LIGHTLAKE THERAPEUTICS INC.
	 	 	 
	 	 	 
	Warrant Holder	 	Roger Crystal, Chief Executive Officer

 

EXHIBIT D

 

Form of Notice of Exercise of Warrant

 

Ladies and Gentlemen:

 

This letter constitutes an unconditional
and irrevocable notice that I hereby exercise the warrant(s) granted to me by Lightlake Therapeutics Inc., a Nevada corporation
(the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the terms of
such warrant(s), I wish to purchase _______________ shares of the common stock covered by such warrant(s) at the exercise price(s)
of US$ ______ per share via cash exercise, for a total aggregate purchase price of US$_______________, which I agree to promptly
provide to the Company.

 

Electronic delivery of this signed notice along with electronic
delivery of such warrant(s) shall have the same exercise effect as surrendering such warrant(s) at the principal office of the
Company together with the properly signed Notice of Exercise of Warrant.

 

These shares should be registered under the Securities Act of
1933, as amended, and delivered as follows:

 

	Name:	 	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Name:Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the "Agreement")
is effective as of October 25, 2013, by and between Advaxis, Inc., a Delaware corporation (the "Company"), and
Gregory T. Mayes, III ("Executive").

 

WHEREAS, the Company and Executive
desire to enter into this Agreement pursuant to which the Company will employ Executive in the capacity, for the period, and on
the terms and conditions set forth herein;

 

NOW, THEREFORE, in consideration
of the premises and mutual covenants and agreements herein contained, the parties hereby agree as follows:

 

1. EMPLOYMENT AND DUTIES. The Company
hereby employs Executive and Executive hereby accepts such employment in the capacity of Chief Operating Officer ("COO"),
and agrees to act in accordance with the terms and conditions hereinafter set forth. During the Term (as defined below), Executive
agrees that he will devote time, attention and skills to the operation of the Business (as defined below) of the Company and that
he will perform such duties, functions, responsibilities and authority in connection with the foregoing as are customarily assigned
to individuals serving in such position and such other duties consistent with Executive’s title and position as the Company’s
Board of Directors (the “Board”) or Chief Executive Officer specify from time to time. For purposes of this
Agreement, the “Business” of the Company shall be defined as the development and commercialization of immunotherapy
drug candidates and related technology based products.

 

Executive represents and warrants that he
is not bound by the terms of any agreement with any previous employer or other party that would limit his abilities to perform
his duties and obligations hereunder. In connection with Executive’s employment, Executive further represents and warrants
that he will not use any confidential or proprietary information of any previous employer.

 

2. TERM. The term of this Agreement
shall commence on the date hereof and shall continue for a period of one (1) year (the “Initial Term”). Thereafter,
this Agreement shall be automatically renewed for one year periods (“Renewal Terms”), unless otherwise terminated
by the Company or Executive upon written notice to the other given not less than ninety (90) days prior to the expiration of the
Initial Term or the applicable Renewal Term of the Agreement. The Initial Term and any Renewal Terms thereof shall be referred
to herein as the "Term."

 

3. COMPENSATION. In consideration
of all the services to be rendered by Executive to the Company hereunder, the Company hereby agrees to pay or otherwise provide
Executive the following compensation and benefits. It is furthermore understood that the Company shall have the right to make any
applicable deductions or withholdings as agreed to by the parties or required by applicable law (including but not limited to Social
Security payments, income tax withholding and other required deductions not in effect or which may become effective by law any
time during the Term) from the following compensation.

 

    	 

    	 

    

 

(a) SALARY. Executive shall receive
an annual salary of Two Hundred Sixty-Five Thousand Dollars and Zero Cents ($265,000.00), plus annual cost of living (COLA—as
determined by the Social Security Administration) salary increases commencing on the one-year anniversary of the execution of this
Agreement ("Base Salary"). The applicable Base Salary shall be reviewed by the Chief Executive Officer and the Compensation
Committee of the Board (the “Compensation Committee”) immediately following the end of the Company’s fiscal year
to determine the annual increase, or decrease consistent with the Company’s decrease in the base salaries of other senior
executives, to the applicable year’s Base Salary; provided, however, that in no event shall such annual increase be less
than the cost of living increase. The applicable Base Salary will be paid in equal installments not less frequently than bi-monthly
in accordance with the Company's salary payment practices in effect from time to time for senior executives of the Company.

 

(b) BONUS PAYMENT. Effective and
commencing upon November 1, 2013, at the end of each fiscal year of the Company, in addition to the Base Salary then in effect,
Executive shall be eligible to receive a bonus payment (the "Bonus Payment") of between 10 and 50% of the applicable
year’s Base Salary (the "Bonus Percentage"). The Bonus Payment, if any, will be paid in accordance with the Company's
bonus payment practices in effect from time to time for senior executives of the Company. It will be awarded in the sole discretion
of the Compensation Committee based on a mutually agreed set of goals established during the first month of each fiscal year, in
consultation with the Chief Executive Officer. Determinations as to whether Executive has met these mutually agreed upon set of
goals will be determined in the sole discretion of the Compensation Committee. Executive must be employed by the Company, without
the occurrence of any of the Events of Termination, as that term is defined below, and without having tendered notice to the Company
of an anticipated Event of Termination, at the time that the Bonus Payment is to be paid to Executive.

 

(c) BENEFIT PLANS. As of the date
hereof, Executive shall be eligible to participate in the Company’s group health insurance plan and any other benefit plan
applicable to the Company’s senior executives.

 

(d) INSURANCE. The Company may secure,
in its own name, or otherwise, and at its own expense, life, health, accident and other insurance covering Executive or Executive
and others. Executive agrees to assist the Company in procuring such insurance by submitting to the usual and customary medical
and other examinations and by signing, as the insured, such applications and other instruments in writing as may be reasonably
required by the insurance companies to which application is made pursuant to such insurance. Executive agrees that he shall have
no right, title, or interest in or to any insurance policies or to the proceeds thereof which the Company many so elect to take
out or to continue on the Executive's life.

 

(e) RESTRICTED STOCK AWARD. Upon
execution and delivery of this Agreement, Executive shall receive a stock award for 150,000 restricted stock units under the terms
and conditions set forth in the Restricted Stock Award Agreement attached hereto as Exhibit A.

 

(f) EXPENSES. Executive shall be
entitled to be reimbursed for all reasonable expenses incurred by him in connection with the fulfillment of his duties hereunder,
including all necessary continuing education and certification costs and related expenses; provided, however, that Executive has
obtained the Company's prior written approval of such expenses and has complied with all policies and procedures related to the
reimbursement of such expenses as shall, from time to time, be established by the Company.

 

    	 

    	 

    

 

(g) VACATIONS AND SICK LEAVE. Executive
shall be entitled to four (4) weeks’ paid vacation annually to be taken in accordance with the Company's vacation policy
in effect from time to time and at such time or times as may be mutually agreed upon by the Company and Executive. Unused vacation
time may not be carried over from year to year. Executive shall also be entitled to sick leave in accordance with the Company’s
sick leave policies in effect from time-to-time.

 

4. TERMINATION.

 

(a) EVENTS OF TERMINATION. This Agreement
and the employment relationship shall terminate on the earliest to occur of the following events (the “Events of Termination”):

 

			(i) expiration of the Term;

 

			(ii) written mutual agreement of the Company and Executive;

 

			(iii) the voluntary resignation by Executive with Good Reason. “Good Reason” shall be defined as: (a) the
failure of the Company to pay Executive any compensation when due, save and except for a disputed claim to compensation; (b) a
significant adverse change in the nature or scope of the authority, powers, functions, responsibilities, or duties attached to
the positions of Executive with the Company as set forth herein; or (c) a material breach by the Company or its successors of a
term or condition of this Agreement.

 

			(iv) the voluntary resignation of Executive without Good Reason;

 

			(v) the death of Executive;

 

			(vi) the disability of Executive. Executive shall be deemed disabled if, as a result of Employee’s incapacity due to
physical or mental illness, Executive shall have been absent from his duties hereunder on a full time basis for a period of one
(1) month or longer;

 

			(vii) the retirement of Executive;

 

			(vii) the termination of Executive’s employment by the Company for “Just Cause,” as determined by the Company
in its sole discretion. “Just Cause” shall include: (a) the failure by Executive to substantially perform his
assigned duties for the Company, which failure has continued for a period of at least fifteen (15) days following written notice
of demand for substantial performance, signed by an officer or director of the Company, has been delivered to Executive specifying
the manner in which Executive has failed to substantially perform; (b) Executive engaging in conduct, which in the Company’s
sole discretion, is demonstrably and materially injurious to the Company, which Executive does not cease following Executive’s
receipt of written notice from the Company specifying the nature of such conduct; (c) behavior constituting gross negligence or
willful misconduct by the Executive during the course of his duties and the term of this Agreement; (d) the misappropriation of
corporate assets or corporate opportunities by Executive or any other acts of dishonesty or breach of Executive’s fiduciary
obligation to the Company; or (e) the involvement of Executive in a felony or a misdemeanor involving moral turpitude (including
the entry of a plea of nolo contendre); or

 

    	 

    	 

    

 

			(viii) the termination of Executive’s employment by the Company without “Just Cause.”

 

(b) EVENTS OF TERMINATION TRIGGERING
SEVERANCE PAYMENT. If the Company terminates Executive's employment without Just Cause, if Executive voluntarily resigns with
Good Reason, or if Executive's employment is terminated due to disability, as that term is defined above, Executive shall be entitled
to receive, provided Executive properly executes and does not revoke a Confidential Separation and Release Agreement in the form
provided by the Company at the time of separation from his employment, in addition to the applicable Base Salary, plus any accrued
but unused vacation time and unpaid expenses (in accordance with Sections 3(e) and (f) hereof) that have been earned by the Executive
as of the date of such termination (“Termination Date”), the following severance payments (the "Severance
Payments"):

 

			(i) equal monthly installments at the applicable Base Salary rate then in effect, as determined on the first day of the calendar
month immediately preceding the day of termination, to be paid beginning on the first day of the month following such Termination
Date and continuing twelve (12) months following the Termination Date (the "Severance Period"). Whenever Severance Payments
are payable to Executive hereunder during a time when Executive is partially or totally disabled, and such disability would entitle
him to disability income payments according to the terms of any plan or policy now or hereafter provided by the Company, the Severance
Payments payable to Executive hereunder shall be inclusive of any such disability income and shall not be in addition thereto,
even if such disability income is payable directly to Executive by an insurance company under a policy paid for by the Company.

 

			(ii) during the Severance Period, health benefits substantially similar to those which Executive was receiving or entitled
to receive immediately prior to termination.

 

			(iii) all stock options held by the Executive will be deemed fully vested and exercisable on the Termination Date and the exercise
period for such stock options will be increased by a period of two years from the Termination Date.

 

			(iv) issuance of all Common Stock earned by the employee that has not yet been issued within four business days of the Termination
Date.

 

(v) removal of all restrictive legends on shares held
by the Executive that qualify for such treatment under Rule 144 of the Securities and Exchange Act of 1934 within 10 business days
of the presentation of such shares to the Company’s transfer agent.

 

    	 

    	 

    

 

(c) EVENTS OF TERMINATION NOT TRIGGERING SEVERANCE PAYMENT.
If Executive’s employment with the Company is terminated for any reason other those specifically enumerated in Section 4(b)
of this Agreement, including, but not limited to, the expiration of the Term, written mutual agreement of the Company and Executive,
the voluntary resignation of Executive without Good Reason, the death or retirement of Executive, or the termination of Executive’s
employment by the company with “Just Cause,” Executive shall not be entitled to receive any compensation other than
his accrued salary through the effective date of such termination, plus any accrued but unused vacation time and unpaid expenses
(in accordance with Sections 3(e) and (f) hereof) that have been earned by the Executive as the date of such termination. Executive
shall also be entitled to the continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C.
§ 1161 et seq. (commonly known as “COBRA”), provided, that, Executive shall be solely responsible for premiums,
costs and expenses associated therewith. The provisions of this Section 4(c) shall be in addition to, and not in lieu of, any other
rights and remedies the Company may have at law or in equity under any other provision of this Agreement in respect of such termination
of employment.

 

5. RESTRICTIVE COVENANTS. Executive
and the Company agree that the Company would suffer irreparable harm and incur substantial damage if Executive were to enter into
Competition (as defined herein) with the Company. Therefore, in order for the Company to protect its legitimate business interests,
Executive agrees as follows:

 

(a) Without the prior written consent of
the Company, Executive shall not, during the period of employment with the Company for any reason, directly or indirectly, invest
or engage in any business that is Competitive (as defined herein) with the Business of the Company or accept employment or render
services to a Competitor (as defined herein) of the Company as a director, officer, agent, employee or consultant or solicit or
attempt to solicit or accept business that is Competitive with the Business of the Company, except that Executive may own up to
five percent (5%) of any outstanding class of securities of any company registered under Section 12 of the Securities Exchange
Act of 1934, as amended.

 

(b) Without the prior written consent of
the Company and upon any termination of Executive's employment with the Company for any reason and for a period of twelve (12)
months thereafter, Executive shall not, either directly or indirectly, (i) invest or engage in any business that is Competitive
(as defined herein) with the Business of the Company, except that Executive may own up to five percent (5%) of any outstanding
class of securities of any company registered under Section 12 of the Securities Exchange Act of 1934, as amended, (ii) accept
employment with or render services to a Competitor of the Company as a director, officer, agent, employee or consultant unless
he is serving in a capacity that has no relationship to that portion of the Competitor's business that is Competitive with the
Business of the Company, or (iii) solicit, attempt to solicit or accept business Competitive with the Business of the Company from
any of the customers of the Company at the time of his termination or within twelve (12) months prior thereto or from any person
or entity whose business the Company was soliciting at such time.

 

(c) Upon termination of his employment with
the Company for any reason, and for a period of twelve (12) months thereafter, Executive shall not, either directly or indirectly,
engage, hire, employ or solicit in any manner whatsoever the employment of an employee of the Company.

 

    	 

    	 

    

 

(d) For purposes of this Agreement, a business
or activity is in "Competition" or "Competitive" with the Business of the Company if it involves,
and a person or entity is a "Competitor", if that person or entity is engaged in, or about to become engaged in,
the research, development, design, manufacturing, marketing or selling of a specific product or technology that resembles, competes,
or is designed to compete, with, or has applications similar to any product or technology for which the Company has obtained or
applied for a patent or made disclosures, or any product or technology involving any other proprietary research or development
engaged in or conducted by the Company during the term of Executive's employment with the Company.

 

6. CONFIDENTIALITY. Executive acknowledges
and agrees that all nonpublic information concerning the business of the Company or any of its affiliates including without limitation,
nonpublic information relating to it or its affiliates’ products, customer lists, pricing, trade secrets, patents, business
methods and cost data, business plans, strategies, drawings, designs, nonpublic information regarding product development, marketing
plans, sales plans, manufacturing plans, management organization (including but not limited to nonpublic data and other information
relating to members of the Board, the Company or any of their affiliates or to management of the Company or any of its affiliates),
operating policies or manuals, financial records, design or other nonpublic financial, commercial, business or technical information
(i) relating to the Company or any of its affiliates or (ii) that the Company or any of its affiliates may receive
belonging to suppliers, customers or others who do business with the Company or any of its affiliates (collectively, the “Confidential
Information”) is and shall remain the property of the Company. Executive recognizes and agrees that all of the Confidential
Information, whether developed by Executive or made available to Executive, other than (i) information that is generally known
to the public, (ii) information already properly in Executive’s possession on a non-confidential basis from a source other
than the Company or its affiliates, which source to Executive’s knowledge is not prohibited from disclosing such information
by a legal, contractual or other obligation of confidentiality to the Company or its affiliates, or (iii) information that can
be demonstrated by Executive to have been independently developed by Executive without the benefit of Confidential Information
from the Company or its affiliates, is a unique asset of the business of the Company, the disclosure of which would be damaging
to the Company. Accordingly, Executive agrees to use such Confidential Information only for the benefit of the Company. Executive
agrees that during the Employment Period and until the sixth anniversary of the date of termination or expiration Executive’s
employment with the Company or its affiliates, Executive will not directly or indirectly, disclose to any person or entity any
Confidential Information, other than information described in clauses (i), (ii) and (iii) above, except as may be required in the
ordinary course of business of the Company or as may be required by law or government authority. If disclosure of any Confidential
Information is requested or required by legal process, civil investigative demand, formal or informal governmental investigation
or otherwise, Executive agrees (i) to notify the Company promptly in writing so that the Company may seek a protective order or
other appropriate remedy, and to cooperate fully, as may be reasonably requested by the Company, in the Company’s efforts
to obtain such a protective order or other appropriate remedy, and (ii) shall comply with any such protective order or other remedy
if obtained. Information concerning the business of the Company or any of its affiliates that becomes public as a result of Executive’s
breach of this Section 6 shall be treated as Confidential Information under this Section 6. Notwithstanding any provision herein
to the contrary, Executive may disclose the terms of this Agreement to the extent necessary to enforce its rights under this Agreement.

 

    	 

    	 

    

 

7. WORKS FOR HIRE. Executive acknowledges
and agrees that all services performed for the Company during the Term are provided on a work for hire basis (as that term is used
in the United States Copyright Act), and that Executive has no right, claim or title, and expressly disavows any such right, claim,
or title, to any such work. If, for any reason, the foregoing is ineffective to confirm the absolute, irrevocable and unconditional
ownership by, or rights of, the Company in any materials created by Executive in connection with such services, or if it should
ever be determined that any of such materials are not a “work-made-for-hire” exclusively owned and authored by the
Company, Executive hereby absolutely, irrevocably and unconditionally assigns (or, to the extent such assignment is or may be prohibited
or limited by any applicable law, hereby absolutely, irrevocably and unconditionally licenses, royalty-free) exclusively to the
Company all of such materials, throughout the universe in perpetuity, without condition, exclusion, limitation or reservation.

 

8. NOTICES. Any notice or other communication
required or permitted to be given hereunder shall be in writing and deemed to have been given when delivered in person or when
dispatched by telegram, electronic mail, or electronic facsimile transfer (confirmed in writing by mail, registered or certified,
return receipt requested, postage prepaid, simultaneously dispatched) to the addressees at the addresses specified below.

 

	 	If to Executive:     Gregory T. Mayes, III
	 	 	[ADDRESS]
	 	 	 
	 	If to the Company:   Daniel J. O’Connor
	 	 	President and Chief Executive Officer
	 	 	Advaxis, Inc.
	 	 	305 College Road East
	 	 	Princeton, NJ 08540

 

or to such other address or fax number as either party may from
time to time designate in writing to the other.

 

9. NON-DISPARAGEMENT AGREEMENT. Except
as otherwise required by law, Executive agrees that he will not make any false, negative or disparaging comments about, and that
he will refrain from directly or indirectly making any comments or engaging in publicity or any other action or activity which
reflects adversely upon, the Company, its employees, agents or representatives. This Non-Disparagement provision applies to comments
made verbally, in writing, electronically or by any other means, including, but not limited to blogs, postings, message boards,
texts, video or audio files and all other forms of communication.

 

10. LEGAL REPRESENTATION. Executive acknowledges
that he was advised to consult with, and has had ample opportunity to receive the advice of, independent legal counsel before executing
this Agreement, and that the Company advised Executive to do so and that Executive has fully exercised that opportunity to the
extent he desired. Executive acknowledges that he had ample opportunity to consider this Agreement and to receive an explanation
from such legal counsel of the legal nature, effect, ramifications, and consequences of this Agreement. Executive warrants that
he has carefully read this Agreement, that he understands completely its contents, that he understands the significance, nature,
effect, and consequences of signing it, and that he has agreed to and signed this Agreement knowingly and voluntarily of his own
free will, act, and deed, and for full and sufficient consideration

 

    	 

    	 

    

 

11. ENTIRE AGREEMENT. This Agreement,
together with Exhibit A, constitutes the entire agreement between the parties hereto relating to the subject matter hereof, and
supersedes all prior agreements and understandings, whether oral or written, with respect to the same. No modification, alteration,
amendment or revision of or supplement to this Agreement shall be valid or effective unless the same is in writing and signed by
both parties hereto.

 

12. GOVERNING LAW. This Agreement
is made and entered into in the State of New Jersey, and shall in all respects be interpreted, enforced, and governed by and continued
and enforced in accordance with the internal substantive laws (and not the laws of choice of laws) of the State of New Jersey applicable
to contracts entered into and to be performed in New Jersey.

 

13. ASSIGNMENT. The rights and obligations
of the parties under this Agreement shall not be assignable without written permission of the other party.

 

14. SEVERABILITY. The invalidity
of any provision of this Agreement under the applicable laws of the State of New Jersey or any other jurisdiction, shall not affect
the other provisions hereby declared to be severable from all other provisions. The intention of the parties, as expressed in any
provision held to be void or ineffective, shall be given such full force and effect as may be permitted by law.

 

15. SURVIVAL. The obligations of
the Company or its successor to pay any Severance Payments required hereunder subsequent to the termination of this Agreement and
the obligations of Executive under Sections 5, 6, and 7 hereof, and all subparts thereof, shall survive the termination of this
Agreement.

 

16. REMEDIES. Executive and the Company
recognize that the services to be rendered under this Agreement by Executive are special, unique, and of extraordinary character,
and that in the event of the breach by Executive of the terms and conditions of Sections 5, 6, and 7 hereof, or any subpart thereof,
the Company shall be entitled, if it so elects, to institute and prosecute proceedings in any court of competent jurisdiction,
to obtain damages for any breach thereof.

 

17. DISPUTE RESOLUTION. Except for
the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction,
or other equitable relief to preserve the status quo or prevent irreparable harm, any and all claims, disputes or controversies
arising under, out of, or in connection with the Agreement, including any dispute relating to production, use or commercialization,
which the parties shall be unable to resolve within sixty (60) days, shall be submitted to good faith mediation. The party raising
such dispute shall promptly advise the other party of such claim, dispute or controversy in a writing, which describes in reasonable
detail the nature of such dispute. By not later than five (5) business days after the recipient has received such notice of dispute,
each party shall have selected for itself a representative who shall have the authority to bind such party, and shall additionally
have advised the other party in writing of the name and title of such representative. By not later than ten (10) business days
after the date of such notice of dispute, the party against whom the dispute shall be raised shall select a mediation firm, company,
or agency in New Jersey, or identify an individual mediator(s), and such representatives shall schedule a date with such firm or
mediator(s) for a mediation hearing. The parties shall enter into good faith mediation and shall share the costs equally. If the
representatives of the parties have not been able to resolve the dispute within fifteen (15) business days after such mediation
hearing, the parties shall have the right to pursue any other remedies legally available to resolve such dispute in either the
Courts of the State of New Jersey or in the United States District Court for the District of New Jersey, to whose jurisdiction
for such purposes Company and Executive each hereby irrevocably consents and submits.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties have
executed this Agreement as of the day and year first above written.

 

	 	 	Advaxis, Inc,
	 	 	a Delaware corporation
	 	 	 
	 	By:  	 
	 	 	/s/ Daniel J. O’Connor
	 	 	Name: Daniel J. O’Connor
	 	 	Title:  President and Chief Executive Officer
	 	 	 
	 	Executive:
	 	 	 
	 	 	/s/ Gregory T. Mayes, III
	 	 	Gregory T. Mayes, III

  

    	 

    	 

    

 

 

EXHIBIT A

 

    	 

    	 

    

 

 

ADVAXIS, INC.

 

RESTRICTED STOCK AWARD

 

The purpose of this Restricted Stock Award
granted by Advaxis, Inc., a Delaware corporation (the “Corporation”) is to further the interests of the
Corporation and its Stockholders by providing incentives in the form of stock awards to persons not previously Employees of the
Corporation, or following a bona fide period of non-employment, as an inducement material to the person’s entering into employment
with the Corporation within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.

 

I. NOTICE
OF GRANT OF RESTRICTED STOCK.

 

	Participant:	Gregory T. Mayes, III
	 	 
	Grant Date	 
	 	 
	Total Number of 

Restricted Stock:	150,000
	 	 
	Vesting Schedule:	Subject to the Terms and Conditions, the restrictions on the Restricted Stock shall expire and the Restricted Stock shall become nonforfeitable (referred to as “Vested Shares”) pursuant to the following schedule:

 

	 	On Grant Date	37,500 Restricted Stock
	 	 	 
	 	On First Anniversary of Grant Date	37,500 Restricted Stock
	 	 	 
	 	On Second Anniversary of Grant Date	37,500 Restricted Stock
	 	 	 
	 	On Third Anniversary of Grant Date	37,500 Restricted Stock

 

	 	The Participant has no right to pro-rated vesting of the Restricted Stock if his  service to the Corporation terminates before any applicable vesting date (regardless of the portion of the vesting period the Participant was in service to the Corporation).  Any unvested portion of the Restricted Stock Award will be forfeited upon Participant’s termination of service to the Corporation.

 

    	- 1 -

    	 

    

 

		II.	TERMS AND CONDITIONS

 

1.            Purpose

 

The purpose of this Restricted
Stock Award is to further the interests of the Corporation and its stockholders by providing incentives in the form of stock awards
to persons not previously Employees of the Corporation, or following a bona fide period of non-employment, as an inducement material
to the person’s entering into employment with the Corporation within the meaning of Rule 5635(c)(4) of the NASDAQ Listing
Rules.

 

2.            Administration

 

2.1           Committee

 

(a)          This
Award shall be administered by the Board. The Board may, however, appoint a Committee to administer the Award which shall consist
of not less than a sufficient number of disinterested members of the Board so as to qualify the Committee to administer this Award
as contemplated by Rule 16b-3 and Section 162(m) of the Code and to that end the Board may limit the participation of Committee
members in the Award to formula based or other awards. The Board may remove members from or add members to the Committee. Vacancies
on the Committee shall be filled by the Board.

 

(b)          The
Board or Committee is authorized to (i) interpret and administer the Award, (ii) grant waivers and accelerations of the Award
and (iii) take any other action necessary for the proper administration and operation of the Award

 

2.2           Effect
of Determination

 

Determination of the
Board or Committee shall be final, binding and conclusive on the Participant. No member of the Board or Committee or any of its
designee shall be personally liable for any action or determination made in good faith with respect to this Award.

 

3.             The
Award

 

3.1           Grant
and Issuance of Shares

 

Upon
the later of (a) the Grant Date and (b) the date the Notice shall have been fully executed, the Participant shall acquire and the
Corporation shall issue, subject to the provisions of this Award Agreement, a number of Shares equal to the Total Number of Restricted
Stock set forth in the Notice. As a condition to the issuance of the Shares, the Participant shall execute and deliver to the Corporation,
along with the Notice, the Assignment Separate from Certificate duly endorsed (with date and number of Shares blank) in the form
attached to the Award Agreement.

 

    	- 2 -

    	 

    

 

3.2           Beneficial
Ownership of Shares; Certificate Registration 

 

The
Participant hereby authorizes the Corporation, in its sole
discretion, to deposit the Shares with the Corporation’s transfer agent, including any successor transfer agent, to be held
in book entry form during the term of the Escrow pursuant to Section 6. Furthermore, the Participant hereby authorizes the
Corporation, in its sole discretion, to deposit, following the term of such Escrow, for the benefit of the Participant with any
broker with which the Participant has an account relationship of which the Corporation has notice any or all Shares which are no
longer subject to such Escrow. Except as provided by the foregoing, a certificate for the Shares shall be registered in the name
of the Participant, or, if applicable, in the names of the heirs
of the Participant.

 

3.3           Issuance
of Shares in Compliance with Law

 

The
issuance of the Shares shall be subject to compliance with all applicable requirements of federal, state or foreign law with respect
to such securities. No Shares shall be issued hereunder if their issuance would constitute a violation of any applicable federal,
state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which
the stock may then be listed. The inability of the Corporation to obtain from any regulatory body having jurisdiction the authority,
if any, deemed by the Corporation’s legal counsel to be necessary to the lawful issuance of any Shares shall relieve the
Corporation of any liability in respect of the failure to issue such Shares as to which such requisite authority shall not have
been obtained. As a condition to the issuance of the Shares, the Corporation may require the Participant
to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation
and to make any representation or warranty with respect thereto as may be requested by the Corporation.         

 

3.4           
No Monetary Payment Required 

 

The
Participant is not required to make any monetary payment (other than to satisfy applicable tax withholding, if any, with respect
to the issuance or vesting of the Shares) as a condition to receiving the Shares, the consideration for which shall be services
actually rendered or future services to be rendered to the Corporation or for its benefit. Notwithstanding the foregoing, if required
by applicable law, the Participant shall furnish consideration in the form of cash or services rendered to the Corporation or for
its benefit having a value not less than the par value of the Shares issued pursuant to the Award.

 

4.            Vesting
of Shares 

 

The
restrictions on the Restricted Stock shall expire and the Restricted Stock shall become nonforfeitable as provided in the Notice.

 

5.            Termination
Of Service And Corporation Reacquisition Right

 

5.1           Termination
of Service 

 

Except
in the event of termination due to Participant’s death and Total Disability, vesting of the Restricted Stock Award shall
cease upon Participant’s termination of service to the Corporation.

 

    	- 3 -

    	 

    

 

5.2           Termination
of Service Due to Participant’s Death or Total Disability

 

In
the event of a termination of service due to Participant’s death or Total Disability, the Shares subject to the Restricted
Stock Award shall immediately be deemed Vested Shares.

 

5.3           Reacquisition
Right 

 

In
the event that (a) the Participant’s service to the Corporation
is terminated or, (b) the Participant, the Participant’s
legal representative, or other holder of Shares acquired pursuant to this Award Agreement, attempts to sell, exchange, transfer,
pledge, or otherwise dispose of (other than pursuant to an Change-in-Control), including, without limitation, any transfer to a
nominee or agent of the Participant, any Shares which are not Vested Shares (“Unvested Shares”),
the Corporation shall automatically reacquire the Unvested Shares, and the Participant shall not be entitled to any payment therefor
(the “Corporation Reacquisition Right”). 

 

6.             Escrow

 

6.1           Appointment
of Agent 

 

To
ensure that Shares subject to the Corporation Reacquisition Right will be available for reacquisition, the Participant and the
Corporation may appoint a person or Corporation as their agent and as attorney-in-fact for the Participant (the “Agent”)
to hold any and all Unvested Shares and to sell, assign and transfer to the Corporation any such Unvested Shares reacquired by
the Corporation pursuant to the Corporation Reacquisition Right. The Participant understands that appointment of the Agent is a
material inducement to make this Restricted Stock Award and that such appointment is coupled with an interest and is irrevocable.
The Agent shall not be personally liable for any act the Agent may do or omit to do hereunder as escrow agent, agent for the Corporation,
or attorney in fact for the Participant while acting in good faith and in the exercise of the Agent’s own good judgment,
and any act done or omitted by the Agent pursuant to the advice of the Agent’s own attorneys shall be conclusive evidence
of such good faith. The Agent may rely upon any letter, notice or other document executed by any signature purporting to be genuine
and may resign at any time.

 

6.2           Establishment
of Escrow 

 

The
Participant authorizes the Corporation to deposit the unvested Shares with the Corporation’s transfer agent to be held in
book entry form, as provided in Section 3.2, and the Participant agrees to deliver to and deposit with the Agent each certificate,
if any, evidencing the Shares and an Assignment Separate from Certificate with respect to such book entry Shares and each such
certificate duly endorsed (with date and number of Shares blank) in the form attached to the Award Agreement, to be held by the
Agent under the terms and conditions of this Section 6 (the “Escrow”).
Upon the occurrence of a Change in Control or a change, as described in Section 8, in the character or amount of any outstanding
stock of the corporation the stock of which is subject to the provisions of this Award Agreement , any and all new, substituted
or additional securities or other property to which the Participant is entitled by reason of his ownership of the Shares that remain,
following such Change in Control or change described in Section 8, subject to the Corporation Reacquisition Right shall be
immediately subject to the Escrow to the same extent as the Shares immediately before such event. The Corporation shall bear the
expenses of the Escrow.

 

    	- 4 -

    	 

    

 

6.3           Delivery
of Shares to Participant 

 

The
Escrow shall continue with respect to any Shares for so long as such Shares remain subject to the Corporation Reacquisition Right.
Upon termination of the Reacquisition Right with respect to Shares, the Corporation shall so notify the Agent and direct the Agent
to deliver such number of Shares to the Participant. As soon as practicable after receipt of such notice, the Agent shall cause
to be delivered to the Participant the Shares specified by such notice, and the Escrow shall terminate with respect to such Shares.

 

7.            Board
Discretion

 

The Board, in its discretion, may accelerate
the vesting of the balance, or some lesser portion of the balance, of the Restricted Stock at any time, subject to the terms of
the Award. If so accelerated, such Restricted Stock will be considered as having vested as of the date specified by the Board.

 

8.          Change
in Control

 

In the event of a Change in Control, one
hundred percent (100%) of the Restricted Stock subject to this Award will vest on the date of the Change of Control. In the event
that any applicable law limits the Corporation’s ability to accelerate the vesting of this Award, this Section 8 will be
limited to the extent required to comply with applicable law. 

 

9.            Tax
Withholding

 

9.1           In
General

 

Regardless
of any action taken by the Corporation with respect to any or all income tax, social insurance, payroll tax, payment on account
or other tax-related withholding obligations (the “Tax Obligations”), the Participant acknowledges that
the ultimate liability for all Tax Obligations legally due by the Participant is and remains the Participant’s responsibility
and that the Corporation (a) makes no representations or undertakings regarding the treatment of any Tax Obligations in connection
with any aspect of the Restricted Stock, including the grant, vesting or settlement of the award, the subsequent sale of shares
acquired pursuant to such settlement, or the receipt of any dividends and (b) does not commit to structure the terms of the
grant or any other aspect of the award to reduce or eliminate the Participant’s liability for Tax Obligations. The Participant
shall pay or make adequate arrangements satisfactory to the Corporation to satisfy all Tax Obligations of the Corporation and
any other Participating Corporation at the time such Tax Obligations arise. In this regard, at the time the award is settled,
in whole or in part, or at any time thereafter as requested by the Corporation or any other Participating Corporation, the Participant
hereby authorizes withholding of all applicable Tax Obligations from payroll and any other amounts payable to the Participant,
and otherwise agrees to make adequate provision for withholding of all applicable Tax Obligations, if any, by each Participating
Corporation which arise in connection with the award. The Corporation shall have no obligation to process the settlement of the
award or to deliver shares until the Tax Obligations as described in this Section have been satisfied by the Participant.

 

    	- 5 -

    	 

    

 

9.2           Withholding
in Shares 

 

Subject
to compliance with applicable law, the Corporation may require the Participant to satisfy all or any portion of the Tax Obligations
by deducting from Shares otherwise deliverable to the Participant in settlement of the Award a number of whole Shares having a
fair market value, as determined by the Corporation as of the date on which the Tax Obligations arise, not in excess of the amount
of such Tax Obligations determined by the applicable minimum statutory withholding rates. 

 

10.         Rights
as Stockholder

 

Neither the Participant
nor any person claiming under or through the Participant will have any of the rights or privileges of a stockholder of the Corporation
in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry
form) will have been issued, recorded on the records of the Corporation or its transfer agents or registrars, and delivered to
the Participant (including through electronic delivery to a brokerage account). Notwithstanding any contrary provisions in this
Terms and Conditions, any quarterly or other regular, periodic dividends or distributions (as determined by the Corporation) paid
on Shares will not affect unvested Restricted Stock, and no such dividends or other distributions will be paid on unvested Restricted
Stock or Restricted Stock that are vested but unpaid. After such issuance, recordation and delivery, the Participant will have
all the rights of a stockholder of the Corporation with respect to voting such Shares and receipt of dividends and distributions
on such Shares.

 

11.         
No Effect on Employment

 

Subject to any employment
contract with the Participant, the terms of such employment will be determined from time to time by the Corporation, or the affiliate
employing the Participant, as the case may be, and the Corporation, or the affiliate employing the Participant, as the case may
be, will have the right, which is hereby expressly reserved, to terminate or change the terms of the employment of the Participant
at any time for any reason whatsoever, with or without good cause. The transactions contemplated hereunder and the vesting schedule
set forth in the Notice do not constitute an express or implied promise of continued employment for any period of time. A leave
of absence or an interruption in service (including an interruption during military service) authorized or acknowledged by the
Corporation or the affiliate employing the Participant, as the case may be, will not be deemed a termination of service for the
purposes of this Award.

 

    	- 6 -

    	 

    

  

12.         Changes
in Shares

 

In the event that as a result of a stock or
extraordinary cash dividend, stock split, distribution, reclassification, recapitalization, combination of the Shares or the adjustment
in capital stock of the Corporation or otherwise, or as a result of a merger, consolidation, spin-off or other corporate transaction
or event, the Restricted Stock will be increased, reduced or otherwise affected, and by virtue of any such event the Participant
will in his capacity as owner of unvested Restricted Stock that have been awarded to him (the “Prior Restricted Stock”)
be entitled to new or additional or different shares of stock, cash or other securities or property (other than rights or warrants
to purchase securities); such new or additional or different Stocks, cash or securities or property will thereupon be considered
to be unvested Restricted Stock and will be subject to all of the conditions and restrictions that were applicable to the Prior
Restricted Stock pursuant to the Notice and Terms and Conditions. If the Participant receives rights or warrants with respect to
any Prior Restricted Stock, such rights or warrants may be held or exercised by the Participant, provided that until such exercise,
any such rights or warrants, and after such exercise, any shares or other securities acquired by the exercise of such rights or
warrants, will be considered to be unvested Restricted Stock and will be subject to all of the conditions and restrictions that
were applicable to the Prior Restricted Stock pursuant to the Notice and Terms and Conditions. The Board in its sole discretion
at any time may accelerate the vesting of all or any portion of such new or additional shares of stock, cash or securities, rights
or warrants to purchase securities or shares or other securities acquired by the exercise of such rights or warrants.

 

13.         Address
for Notices

 

Any notice to be given to the Corporation
under the terms of this Award shall be addressed to the Corporation, in care of Daniel J. O’Connor, President and Chief Executive
Officer, Advaxis, Inc., 305 College Road East, Princeton, NJ, 08540 or at such other address as the Corporation may hereafter designate
in writing.

 

14.         Award
is not Transferable

 

This Award and the rights and privileges conferred
hereby shall not be sold, pledged, assigned, hypothecated, transferred or disposed of any way (whether by operation of law or otherwise)
and shall not be subject to sale under execution, attachment or similar process.. Upon any attempt to sell, pledge, assign, hypothecate,
transfer or otherwise dispose of this Award, or any right or privilege conferred hereby, or upon any attempted sale under any execution,
attachment or similar process, this Award and the rights and privileges conferred hereby immediately will become null and void.

 

15.         Binding
Agreement

 

Subject to the limitation on the transferability
of this Award contained herein, the Notice and this Terms and Conditions will be binding upon and inure to the benefit of the heirs,
legatees, legal representatives, successors and assigns of the parties hereto.

 

    	- 7 -

    	 

    

 

16.         Additional
Conditions to Issuance of Certificates for Shares

 

The Corporation will not be required to issue
any certificate or certificates (which may be in book entry form) for Shares hereunder prior to fulfillment of all the following
conditions: (a) the admission of such Shares to listing on all stock exchanges on which such class of stock is then listed; (b)
the completion of any registration or other qualification of such Shares under any U. S. state or federal law or under the rulings
or regulations of the Securities and Exchange Commission or any other governmental regulatory body, which the Board will, in its
sole discretion, deem necessary or advisable; (c) the obtaining of any approval or other clearance from any U. S. state or
federal governmental agency, which the Board will, in its sole discretion, determine to be necessary or advisable; and (d) the
lapse of such reasonable period of time following the date of vesting of the Restricted Stock as the Board may establish from time
to time for reasons of administrative convenience.

 

17.         Legends.

 

The
Corporation may at any time place legends referencing the Corporation, the Corporation Reacquisition Right, the Right of First
Refusal, and any applicable federal, state or foreign securities law restrictions on all certificates representing the shares.
The Participant shall, at the request of the Corporation, promptly present to the Corporation any and all certificates representing
the shares in the possession of the Participant in order to carry out the provisions of this Section. 

 

18.         Agreement
Severable

 

In the event that any
provision in the Notice or the Terms and Conditions is held invalid or unenforceable, such provision will be severable from, and
such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Award.

 

19.         Modifications
to the Award

 

This Notice and the Terms
and Conditions constitute the entire understanding of the parties on the subjects covered. The Participant expressly warrants that
he or she is not accepting this Award in reliance on any promises, representations, or inducements other than those contained herein.
Modifications to this Award can be made only in an express written contract executed by a duly authorized officer of the Corporation.
..

 

20.         Arbitration

 

Any and all disputes
whatsoever between a Participant and the Corporation concerning the administration of this Award, the interpretation and effect
of the Notice and Terms and Conditions or the rights of Participant under the Award shall be finally determined before one neutral
arbitrator in Mercer County, State of New Jersey, under the rules of commercial arbitration of the American Arbitration Association
then in effect and judgment upon any award by such arbitrator may be entered in any Court having jurisdiction or application may
be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. The arbitrator hereunder
shall have no power or authority to award consequential, punitive or statutory damages.

 

    	- 8 -

    	 

    

 

21.         Counterparts

 

The
Award Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

22.         Governing
Law

 

This Award and the
rights of the Corporation and the Participants shall be governed and interpreted in accordance with the laws of the State of New
Jersey.

 

_________________________

 

This Award is granted
to Participant as an inducement material to his entering into employment with the Corporation within the meaning of Rule 5635(c)(4)
of the NASDAQ Listing Rules. In addition, notwithstanding any other provision of the Award to the contrary, the Restricted Stock
are granted either by a majority of the Corporation’s independent directors or by the independent compensation committee
of the Board within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules.

 

By signing below, Participant:
(a) acknowledges receipt of, and represents that Participant has read and is familiar with the terms and conditions of the Award,
(b) accepts the Award subject to all of the terms and conditions set forth herein, and (c) agrees to accept as binding, conclusive
and final all decisions or interpretations of the Board upon any questions arising under the Award.

 

	advaxis, Inc. 	 	PARTICIPANT
	 	 	 
	 	 	 
	 	 	 
	By: Daniel J. O’Connor	 	Signature
	Its President and Chief Executive Officer	 	 
	 	 	Date:	 
	 	 	 
	Address:	305 College Road East	 	Address:	 
	 	Princeton, NJ 08540	 	 	 

 

 

 

    	- 9 -

    	 

    

 

APPENDIX

 

Definitions

 

a)  “Award” means
this Restricted Stock Award.

 

b)  “Beneficiary”
means, where a Participant is within respect to any Award not forfeitable by its terms on the death of the Participant entitled
to any unpaid portion thereof, such person or persons entitled thereto under the Participant’s will or under the laws of
descent and distribution;

 

c)  “Board” means
the Board of Directors of the Corporation.

 

d)  “Change in Control”
means a change in ownership or control of the Corporation effected through any of the following transactions:

 

i.            a
merger, consolidation or other reorganization, unless securities representing more than fifty percent (50%) of the total combined
voting power of the voting securities of the successor Corporation are immediately thereafter beneficially owned, directly or indirectly,
by the persons who beneficially owned the Corporation’s outstanding voting securities immediately prior to such transaction,
or

 

ii.         a
sale, transfer or other disposition of all or substantially all of the Corporation’s assets in liquidation or dissolution
of the Corporation, or

 

iii.         the
acquisition, directly or indirectly by any person or related group of persons (other than the Corporation or a person that directly
or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership of securities
possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant
to a transfer of the then issued and outstanding voting securities of the Corporation by one or more of the Corporation’s
Stockholders, or

 

iv.         during
any period of two (2) consecutive years, individuals who, at the beginning of such period, constitute the Board (the "Incumbent
Board") cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director
of the Board subsequent to the date of the grant of this Award whose election, or a nomination for election by the Corporation's
Stockholders, was approved by the vote of at least a majority of the directors then comprising the Incumbent Board (other than
an election or nomination of any individual whose initial assumption of office is in connection with an actual or threatened election
contest relating to the election of the directors of the Board, as such terms are used in Rule 14a-11 of Regulation 14A
promulgated under the Exchange Act) shall be, for these purposes, considered as though such person were a member of the Incumbent
Board.

 

Anything in the foregoing to the contrary
notwithstanding, a transaction shall not constitute a Change in Control if its sole purpose is to change the legal jurisdiction
of the Corporation’s incorporation or to create a holding Corporation that will be owned in substantially the same proportions
by the persons who held the Corporation’s securities immediately before such transaction.

 

    	- 1 -

    	 

    

 

e)    “Code” means the
United States Internal Revenue Code of 1986, as amended and in effect from time to time, or any successor statute.

 

f)       “Committee”
means the Committee of the Board or any successor committee as described in Section 3.1, or, if there shall be no such Committee,
the Board.

 

g)   “Corporation”
means Advaxis, Inc., a Delaware corporation, or any successor corporation, and its subsidiaries and affiliates, incorporated or
otherwise, in which the Corporation shall own directly or indirectly at least fifty percent (50%) of the interests.

 

h)   “Employee” means
any individual who is a salaried employee on the payroll of the Corporation.

 

i)      “Exchange
Act” means the Securities Exchange Act of 1934, as amended and in effect from time to time, or any successor statute.

 

j)     
“Rule 16b-3” means such rule as promulgated by the Securities and Exchange Commission under the Exchange Act
as now in force or as such regulation or successor regulation shall be hereafter amended.

 

k)    “Shares” means
the shares of common stock of the Corporation, par value $0.001 per share, and such other securities as may be substituted (or
resubstituted) for Shares pursuant to Section 14 hereof

 

l)     
“Totally Disabled” means a permanent and total disability within the meaning of Section 22(e)(3) of the
Code, provided that the Board or Committee in its discretion, may determine whether a permanent and total disability exists in
accordance with uniform and non-discriminatory standards adopted by the Board or Committee from time to time.

 

    	- 2 -

    	 

    

 

ASSIGNMENT SEPARATE FROM CERTIFICATE

 

FOR VALUE RECEIVED the undersigned does
hereby sell, assign and transfer unto ___________________________________________________________________________

 

___________________________________________________ (_________________)
shares of the Shares of Advaxis, Inc. standing in the undersigned’s name on the books of said corporation represented by
Certificate No. __________________ herewith and does hereby irrevocably constitute and appoint ________________________________
Attorney to transfer the said stock on the books of said corporation with full power of substitution in the premises.

 

	Dated:	 	 

 

	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	 
	 	Print Name

 

    	- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]